Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: A retrospective study

Clinical Nephrology

Volumn 85, Issue 1, 2016, Pages 38-43

  Hagan, Amanda E ^a   Farrington, Crystal A ^b   Wall, Geoffrey C ^c   Belz, Mark M ^d  

^a IOWA METHODIST MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c DRAKE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Adverse effects; Hyperkalemia; Sodium polystyrene sulfonate

Indexed keywords

BICARBONATE; CALCIUM; FUROSEMIDE; INSULIN; POLYSTYRENESULFONATE SODIUM; SALBUTAMOL; CATION EXCHANGE RESIN; POLYSTYRENE DERIVATIVE; POLYSTYRENESULFONIC ACID; POTASSIUM;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERNATREMIA; HYPOGLYCEMIA; HYPOKALEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; ACUTE DISEASE; AGED; BLOOD; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; INTESTINE; NECROSIS; PATHOLOGY;

ACUTE DISEASE; AGED; CATION EXCHANGE RESINS; FEMALE; HUMANS; HYPERKALEMIA; HYPERNATREMIA; HYPOKALEMIA; INTESTINES; MALE; NECROSIS; POLYSTYRENES; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84957866036     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108628     Document Type: Article

References (14)

1. Afonzo A, et al. Clinical Practice Guidelines: Treatment of Acute Hyperkalemia in Adults. UK Renal Association. March 2014. Accessed from: http:// www.renal.org/guidelines/joint-guidelines/treatment- of-acute-hyperkalaemia-in-adults #sthas h.5 kbKg nI3.dpbs.
2. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant. 2003; 18: 2215-2218.
3. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia:are they safe and effective? J Am Soc Nephrol. 2010; 21: 733-735.
4. Einbinder Y, Korzets Z, Goodman DJ, Benchetrit S. Sodium polystyrene sulfonate - is it truly effective treatment for hyperkalemia? Clin Nephrol. 2015; 83: 71-72.
5. Guidelines for the treatment of hyperkalemia in adults. CREST: Clinical Resource Efficiency Support Team. 2005. http://www.dhsspsni.gov. uk/hyperkalaemia-booklet.pdf.
6. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron. 2002; 92 (6): 33-40.
7. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009; 339 (6): b4114.
8. Kayexalate (sodium polystyrene sulfonate) powder. FDA. 2011. http://www.fda.gov/Safety/Med-Watch/SafetyInformation/ucm186845.htm.
9. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126:264 e9-24.
10. Kjeldsen K. Hypokalemia and sudden cardiac death. Exp Clin Cardiol. 2010; 15: e96-e99.
11. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014; 347: 93-100.
12. Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol. 1998; 9: 1924-1930.
13. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014; 312: 2223-2233.
14. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015; 372: 211-221.